Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10829557 | 1.00 | MMP8 (0.42) | MMP8DGAT1GRM2GRM3SMN1; SMN2 | |
| SCHEMBL4374469 | 1.00 | MMP8 (0.42) | MMP8DGAT1GRM2GRM3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1629537 | 0.98 | MMP8 (0.41) | MMP8DGAT1GRM2GRM3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27799052 | 0.98 | MMP8 (0.41) | MMP8DGAT1GRM2GRM3SMN1; SMN2 | |
| SCHEMBL28777358 | 0.83 | MMP8 (0.38) | MMP8GRM2GRM3 | |
| SCHEMBL10594002 | 0.82 | SMN1; SMN2 (0.38) | MMP8DGAT1SMN1; SMN2 | |
| SCHEMBL27506909 | 0.81 | DGAT1 (0.34) | MMP8DGAT1 | |
| SCHEMBL6593955 | 0.81 | DGAT1 (0.34) | MMP8DGAT1 | |
| SCHEMBL12319861 | 0.79 | MMP8 (0.40) | MMP8DGAT1GRM2GRM3AR | |
| SCHEMBL6594108 | 0.79 | MMP8 (0.56) | MMP8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3292124-B1 | 6H-ISOCHROMENO[3,4-C]PYRIDINES AND BENZO[C][1,7]NAPHTHYRIDIN-6-(5H)-ONES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| CN-108912111-A | compounds and pharmaceutical compositions | 铁木医药有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105408328-B | sGC stimulators | 铁木医药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| EP-3292124-A2 | FUSED PYRIDINES AS ADAPTOR ASSOCIATED KINASE 1 (AAK1) INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| CN-102066345-B | Azolidine derivatives as NMDA antagonists | BIOTECHNOLOGY RES CO LTD | 2013-07-17 | — | — | CN | disclosed |
| CN-102066345-A | Azolidine derivatives as NMDA antagonists | UNIV HONG KONG SCIENCE & TECHN | 2011-05-18 | — | — | CN | disclosed |
| WO-2009141575-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141575-A1 | INHIBITORS OF PLK | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | WO | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | MMP8 997/4885DGAT1 468/4885GRM2 3731/4885 |
| US-10174044-B2 | Fused pyridines as kinase inhibitors | AAK1, NCK1, ADCK1 | MMP8 4461/4885DGAT1 2935/4885GRM2 1598/4885 |
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | MMP8 4461/4885DGAT1 2935/4885GRM2 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.